Sujentec Establishes JV with Chinese Healthcare Specialist to "Fully Enter Local Telemedicine Market"

[Asia Economy Reporter Yoo Hyun-seok] SuzenTech is partnering with Jissbon, a subsidiary of LifeStyles, the world's second-largest condom company, to actively enter the telemedicine market targeting 680 million Chinese women.

On the 29th, SuzenTech announced that it has signed a contract to establish a joint venture (JV) with Jissbon, a Chinese healthcare specialist company, to enter the local female hormone diagnostic business.

Through the newly established "Zhuhai Nakboksa Diagnostic Technology Co., Ltd.," SuzenTech plans to produce and sell its self-developed female hormone diagnostic product "Surearly® Smart" within China.

Surearly Smart is the world's first female hormone diagnostic device that measures five types of female hormones, including estrogen and progesterone, to manage various female diseases. It is small and portable, offers excellent measurement performance, and provides a total service for managing overall women's health by allowing users to check their hormone patterns through a mobile app.

A SuzenTech official stated, "With the establishment of this JV, we expect to secure equity through technology transfer and generate at least 11 billion KRW in revenue from contract fees, milestones, and royalties," adding, "As the income level of Chinese people has recently increased, interest in personal health has grown, leading to a surge in demand for personal care products. We will do our best to ensure the successful market settlement of Surearly Smart."

He continued, "China is expected to become the world's second-largest telemedicine market after the United States," and added, "The JV established this time will become an important base for SuzenTech's entry into the Chinese market."

Meanwhile, Jissbon, which established the joint venture with SuzenTech, is a Chinese healthcare company founded in 1998. It produces and sells feminine cleansers, erectile dysfunction treatments, condoms, and is an affiliate invested in by Humanwell Group, a major Chinese pharmaceutical company.

This content was produced with the assistance of AI translation services.